Important Notice

Drug Tariff.com is not affiliated in any way with the NHS Business Services Authority. It is merely a portal for useful information relating to the Drug Tariff.

If you have found this site and were looking for the official NHS Business Services Authority website, please click here.

Drug Tariff Data

The Generic Prices, 28 Day Prescribing Costs and Part VIII are available in the registered users area.

Not a member? Click register at the right of this page to join.
Registration is free and only takes 30 seconds.

Dispex 2012

The annual Dispex conference and exhibition is taking place on Saturday 12th May 2012 at the Chesford Grange Hotel in Kenilworth, Warwickshire.

 

Visit www.dispex2012.com to book your place!

Class 1 drug alert issued for Xigris (drotrecogin alfa) 5mg and 20mg powder for infusion

The Medicines and Health products Regulatory Agency (MHRA) has issued a class 1 drug alert for Xigris (drotrecogin alfa) 5mg and 20mg powder for infusion (Eli Lilly and Co Ltd). Click here for further details of the alert.

This alert has been issued because new clinical trial findings show a lack of efficacy and call into question the risk-benefit profile of Xigris powder for infusion.

Patients currently being treated with the medicine should discontinue treatment. Pharmacists should return any unused stock to the distributor. We understand this is a hospital-only product not likely to be used by community pharmacists or general practitioners.